Covid-19 in children aged 5-11: Examining the issues surrounding vaccination and public health policyArticle Published on 2022-09-012022-11-16 Journal: Paediatric respiratory reviews [Category] 변종, [키워드] adverse event age association children Complication COVID COVID-19 COVID-19 cases Critical database death deaths detrimental eligible Epidemiology Examining FDA approval Health help hospitalizations Hospitalized information mechanical ventilation moderate morbidity much lower myocarditis occur parent pediatric proportion provided public health risk severe cases vaccination vaccination rate variants waning immunity [DOI] 10.1016/j.prrv.2022.03.002 PMC 바로가기
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccinationArticle Published on 2022-09-012022-10-05 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, [키워드] Administered Adverse Anti-RBD IgG AZD1222 binding BNT162b2 boost booster booster vaccination Booster vaccine cellular response COVID-19 COVID-19 vaccines domain dose elicited enrolled evade event Evidence healthy Heterologous heterologous booster highest homologous homologous or heterologous humoral Immunity Immunoglobulin individual individuals Messenger RNA mRNA mRNA-1273 Mutation NAb NAbs neutralization neutralizing antibody objective omicron overcome participant peaked persistence provided RBD reactogenicity reduction Result SARS-CoV-2 significantly T cell response T cells Total vaccination Vaccinations Vaccine vaccine dose Vaccines variant variants waning immunity [DOI] 10.1016/j.ijid.2022.07.038 [Article Type] Article
Expert review on global real-world vaccine effectiveness against SARS-CoV-2Review Published on 2022-09-012023-07-09 Journal: Expert review of vaccines [Category] COVID19(2023년), [키워드] AZD1222 COVID-19 mRNA omicron real-world Southeast Asia vaccine effectiveness variants of concern vector waning immunity [DOI] 10.1080/14760584.2022.2092472 [Article Type] Review
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort studyArticle Published on 2022-09-012022-11-16 Journal: PLoS Medicine [Category] SARS, 변종, [키워드] 95% confidence interval age Alpha variant Analysis BNT162b2 mRNA calculated CIs cohort study Comorbidity contagious coronavirus 2 COVID-19 COVID-19 hospitalization Delta delta variant Denmark dose doses Effectiveness estimate geographical region group groups Hospitalization Infection mRNA-1273 nonrandomized study Occurrence omicron provided Regression model respiratory SARS-CoV-2 SARS-COV-2 infection Sex short-lived sustained the vaccine uninfected unique vaccinated individuals vaccination Vaccination Status vaccine dose variant variants waned waning immunity was obtained was used [DOI] 10.1371/journal.pmed.1003992 PMC 바로가기
Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant델타 변종에 대한 코로나바이러스 질병 2019(COVID-19) 백신의 비교 효과Comparative Study Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Against Analysis approved BNT162b2 Comparative comparative effectiveness contributed coronavirus coronavirus disease Coronavirus disease 2019 covariate COVID-19 COVID-19 hospitalization COVID-19 vaccine COVID-19 vaccines Cox model declined Delta delta variant effective Effectiveness Efficacy hazard ratio Healthcare system Hospitalization Immunity impacted Infection IPW Kaplan-Meier lack large cohort lower risk Medicine Moderna mRNA mRNA-1273 mRNA-1273 vaccine mRNA-based vaccine mRNA-based vaccines Patient Pfizer-BioNTech recipient recipients risk SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus significantly vaccination Vaccine variant waning immunity [DOI] 10.1093/cid/ciac106 PMC 바로가기 [Article Type] Comparative Study
Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era오미크론 시대 영국에서 SARS-CoV-2 전파의 중기 역학 모델링Article Published on 2022-08-192022-09-11 Journal: Nature Communications [Category] SARS, 변종, 치료법, [키워드] accelerated assumption behavioural booster vaccination booster vaccinations COVID-19 death Effectiveness England epidemiological data expected Hospital admission Hospital admissions infection level offered omicron Omicron variants rising SARS-CoV-2 disease SARS-CoV-2 infections SARS-CoV-2 transmission seasonality Spread variant waning immunity [DOI] 10.1038/s41467-022-32404-y PMC 바로가기 [Article Type] Article
A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 백신을 강화하기 위한 정밀 보조제 접근법Article Published on 2022-08-152022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] acute respiratory syndrome adjuvant adjuvants caused coronavirus coronavirus 2 COVID-19 drug Effect effective Emergency use authorization ENhance food immune system Inclusion limitations Mortality Multiple Older pandemic pediatric Population populations Precision precision vaccines reflect respiratory robust Safe SARS-CoV-2 SARS-CoV-2 vaccine vaccine doses Vaccines Vulnerable populations waning immunity [DOI] 10.1093/cid/ciac342 PMC 바로가기 [Article Type] Article
COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivationCOVID-19 mRNA 부스터 백신은 일시적인 CD8+ T 효과기 세포 반응을 유도하는 동시에 후속 재활성화를 위해 메모리 풀을 보존합니다Article Published on 2022-08-082022-09-11 Journal: Nature Communications [Category] 변종, 진단, 치료기술, [키워드] activated analyzed boost booster vaccination Booster vaccine Breakthrough infection breakthrough infections CD8 CD8+ Cell conserved COVID-19 COVID-19 vaccination Delta dose effector cell elicit followed by Immunity immunization individual induce memory mRNA mRNA vaccine Neutralizing antibody response neutralizing antibody responses not affected omicron recall receiving response robust stem cell subsequent T cell T cell response T cell responses T cells T memory cells vaccination variants of concern waning immunity [DOI] 10.1038/s41467-022-32324-x PMC 바로가기 [Article Type] Article
Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases전신 자가면역 류마티스 질환이 있는 개인에서 SARS-CoV-2 백신 접종 후 면역원성, 돌발성 감염 및 기저 질환 발적Review Published on 2022-08-012022-09-12 Journal: Current opinion in pharmacology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome Autoimmune Breakthrough infection clinical trial coronavirus detrimental disease Disease activity doses humoral immunogenicity immune response immunogenicity Immunosuppressed Immunosuppression Impact include individual Patient reduce rheumatic disease SARS-CoV-2 SARS-CoV-2 vaccination severity underlying disease vaccination Vaccine waning immunity [DOI] 10.1016/j.coph.2022.102243 PMC 바로가기 [Article Type] Review
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies회복기 및 백신 혈청 및 단일 클론 항체에 의한 SARS-CoV-2 오미크론 하위 변이체 BA.1 및 BA.2의 제한된 중화Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 addition antibody BA.1 BA.2 BNT162b2 booster booster dose booster vaccination breakthrough infections Casirivimab Cell Complete convalescent convalescent sera Delta dominant dose education Efficacy elicited exhibited expressing Frankfurt Imdevimab Immunity in vitro study individual infection with SARS-CoV-2 Limited majority median monoclonal antibodies monoclonal antibody monoclonal antibody therapy Mutation neutralisation neutralise neutralising neutralizing capacity omicron Omicron variants reduced Region SARS-CoV-2 sera serum Sotrovimab specific resistance Spike protein supported tested the SARS-CoV-2 the spike protein therapy TMPRSS2 university vaccination Vaccine Vaccines variants variants of SARS-CoV-2 waning immunity [DOI] 10.1016/j.ebiom.2022.104158 PMC 바로가기 [Article Type] Article